Home / Health / Custom Cancer Vaccine Halves Melanoma Return Risk
Custom Cancer Vaccine Halves Melanoma Return Risk
23 Oct
Summary
- Personalized cancer vaccine significantly reduces melanoma recurrence.
- Vaccine uses Nobel Prize-winning mRNA technology.
- Study shows 42% reduction in cancer return risk after two years.
A revolutionary personalized cancer vaccine, intismeran, is significantly reducing the chances of melanoma returning for patients. Developed using Nobel Prize-winning mRNA technology, similar to COVID-19 vaccines, this custom-brewed treatment targets gene mutations unique to each patient's tumor.
In a major international study involving over 1,100 participants, the vaccine, administered alongside Merck's Keytruda immunotherapy, demonstrated a 42% reduction in the risk of melanoma recurrence within two years. Patients receiving the vaccine showed an 82% survival rate without recurrence compared to 70% with Keytruda alone.
Side effects reported were typical of mRNA vaccines, including sore arm and fatigue. While Moderna's shares saw a dip following the full results release, experts herald this as a new frontier in oncology, with potential applications for various other cancers.
